COVID-19 Vaccination Plan

South Dakota Department of Health

October 27, 2020

We will begin in just a few moments. Thanks! Information is current as of 10.27.2020



Agenda

- COVID 19 Vaccines
- Vaccination Presentations
- SD COVID Vaccination Plan
- Vaccination Phases
- Vaccine storage and handling
- Provider Enrollment
- Documentation of COVID Vaccination
- Q&A



COVID 19 Vaccines/Phase 3

Pfizer mRNA Vaccine

Moderna mRNA Vaccine

AstraZeneca vector (adenovirus) Vaccine

Johnson & Johnson recombinant vector

(adenovirus) vaccine

OWS/CDC contracted with 6 manufacturers to produce 800 million doses



Vaccination Presentations

- Early doses of vaccine will be in multi dose vials
- There will be variable vaccine storage requirements --70C, -20C, 2-8C
- Stability testing is still being conducted and storage requirements and expiration dates may change
- May be other presentations of vaccine available later: SDV, SDS



SD COVID Vaccination Plan

- Section 1: COVID-19 Vaccination Preparedness Planning
- Section 2: COVID-19 Organizational Structure and Partner Involvement
- Section 3: Phased Approach to COVID-19 Vaccination
- Section 4: Critical Populations
- Section 5: COVID-19 Provider Recruitment and Enrollment
- Section 6: COVID-19 Vaccine Administration Capacity
- Section 7: COVID-19 Vaccine Allocation, Ordering, Distribution, and Inventory Management
- Section 8: COVID-19 Vaccine Storage and Handling
- Section 9: COVID-19 Vaccine Administration Documentation and Reporting
- Section 10: COVID-19 Vaccination Second-Dose Reminders
- Section 11: COVID-19 Requirements for IISs or Other External Systems
- Section 12: COVID-19 Vaccination Program Communication
- Section 13: Regulatory Considerations for COVID-19 Vaccination
- Section 14: COVID-19 Vaccine Safety Monitoring
- Section 15: COVID-19 Vaccination Program Monitoring



Target Populations for phase 1


- Healthcare personnel
- Other essential workers
- LTC Residents and staff
- Underlying medical conditions
- Persons 65 and older
- Persons from racial and ethnic minority groups
- Persons from Tribal communities
- Persons incarcerated
- Homeless shelters
- Colleges and Universities
- Persons living or working in congregate settings
- Rural communities
- Persons with disabilities
- Un/underinsured



Vaccination Phases

Illustrative scenario for planning purposes; will be adapted based on the clinical / manufacturing information on all OWS candidates and vaccine prioritization

Distribution will Adjust as volume of vaccine doses increases, moving from targeted to broader populations reached (phased approach)



- Imperative to maintain appropriate temperatures
- Temperatures monitored with a digital data logger
- Temperatures recorded twice daily
- Details on working through a temperature excursion are forthcoming



	Vaccine availability under EUA by				
Candidate	End of Nov 2020	End of Dec 2020	Notes		
Vaccine A	10M–20M doses	20M–30M doses	Ultra-cold (-75 °C) storage requirements, for large sites only		

SHIPMENT

3 separately acquired components (mixed on site)

- 1. Vaccine
 - 2mL vial, Multidose vials (5 doses/vial)
 - Direct to site from manufacturer (on dry ice) in thermal shipping container
 - Thermal shipping container estimated specs: 400mm X 400mm X 560mm
- **2.** Diluent and ancillary supply kits (for administration and mixing)
 - Direct to site from the US Government (USG) at room temperature)
- Thermal shipping container should be returned once use is completed. Instructions for mail back and labels will be forthcoming.

ON-SITE VACCINE STORAGE

Ultra-Low Temp Frozen (-90°C to -60°C)

- Freezer units capable of ultra-cold temperatures (UCT)
- The shipping container (thermal shipper) may be used to store vaccines:
 - Once received, thermal shipping container should be replenished with pelleted dry ice within 24 hours
 - O Containers may only be opened two times a day.
 - Containers should be replenished with dry ice every 5 days to maintain required temperature.
 - Total amount of dry ice needed per thermal shipper 'recharge' is ~23kg.
 - Container may be recharged up to 3 times (once upon receipt, and two more time there after)
- Temperature Monitoring needs to happen in alignment with CDC guidance, irrespective of re-icing
 - Thermal shipping container may be monitored using temperature probes on the container, in alignment with guidance provided by CDC and information provided by the manufacturer.
 - Direct handling of dry ice needed for recharging the containers will require the use of appropriate PPE



	Thawed but NOT diluted (2–8 °C)	
	 Product may be removed from the ULT or thermal shipping container and thawed and stored at 2—8°C for up to 5 days (discard unused doses after 5 days) Cannot return to UCT storage or thermal shipper once thawed 	
	Diluted (room temperature)	
	 If removed directly from UCT, vaccine must be thawed ~30minutes at room temperature before dilution. Once vaccine is at room temperature, it must be diluted within 2 hours. Must use diluted vaccine within 6 hours (discard any unused, diluted vaccine after 6 hours) 	
ORDERS	ADMINISTRATION	
Large quantities, to large administration	2-dose series (21 days between doses)	
 Sites only Minimum order: ~1,000 doses Maximum order: ~5,000 doses 	 On-site mixing required; dilute with diluent just prior to administration; all 5 doses must be administered within 6 hours of dilution; remainder of diluted vaccine should be discarded. Multidose vial contains 5 doses 	
	Administer by intramuscular (IM) injection	

INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINE ADMINISTRATION SITES

NOTE: primary administration sites may consider providing vials to other sites HOWEVER all cold chain should be maintained and logged in accordance with the information provided above.

Healthcare personnel — public health, closed point of dispensing (POD), temporary/off-site vaccination clinics + potential for mobile clinics

Other essential workers — public health, closed POD, temporary/off-site vaccination clinics + potential for mobile clinics

Adults with underlying medical conditions and people 65 years of age and older — open PODs in strategic locations, potential for mobile clinics to long-term care facilities or partnership with pharmacy onsite clinics for LTCFs, correctional/detention facilities, and other congregate settings



	Vaccine availability under EUA by					
Candidate	End of Oct 2020	End of Nov 2020	End of Dec 2020	Notes		
Vaccine B	~1M doses	~10M doses	~15M doses	Central distributor capacity required (-20		
		Va	ccine B			
SHIPMENT			ON-SITE VACCINE STORAGE			
2 separately shipped	d components		Frozen (-20 °C)			
1. Vaccine			Storage in shipping container OK			
 To central distributor (at -20 °C) 			Refrigerated (2–8 °C)			
Multidose vials (10 doses/vial)			Must use within 14 days			
2. Ancillary supply kits			Room temperature			
Direct to site from USG (at room temperature)		n temperature)	 Must use within 6 hours (discard any unused vaccine after 6 hours) 			
ORDERS			ADMINISTRATION			
Central distribution	capacity required		2-dose series (28 days between doses)			
Required by Dec			No on-site mixing required			
Maintained at -20 °C			Administer by IM injection			
Healthcare personn vaccination clinics + r Other essential wor vaccination clinics	el — healthcare clinics nobile clinics kers (specifics TBA) —	+ healthcare occupationa occupational health + hos	·	th, closed POD, temporary/off-site closed POD, temporary/off-site cy partners		



Product Packaging Overview



Primary Packaging



Secondary Packaging "Single Tray"



Tertiary Container: Thermal Shipper









	Item	Description
	0	Dry Ice Pod
	2	Payload (Vial Trays)
	3	Inner Lid
	4	Payload Sleeve
	5	Outer Carton
and and		

- 2 mL type 1 glass preservative free multi-dose vial (MDV)
- MDV has 0.45 mL frozen liquid drug product
- · 5 doses per vial after dilution

- Single tray holds 195 vials
- 975 doses per tray
- A smaller tray, containing 25 vials (125 doses) is in development with estimated availability in early 2021

- Minimum 1 tray (975 doses) or up to 5 trays (4875 doses) stacked in a payload area of the shipper
- Payload carton submerged in dry ice pellets
- Thermal shipper keeps ULT (-75±15°C) up to 10 days if stored at 15°C to 25°C temperatures without opening.
- Thermal shippers are reusable and designed to be a temporary storage containers by replenishing dry ice






Please see slide 2 for important limitations with respect to this presentation.



Ultra Low Temperature Thermal Shipper – Overview of Pack Out





Weights and Dimensions				
Tare Weight (Inc. Dry-Ice)	8.5kg (31.5kg)			
Volumetric Weight	15.0kg			
Payload Space L x W x H	245x245x241mm			
Shipper Dimensions L x W x H	400x400x560mm			







Vaccine Storage Options* At the Point of Vaccination




- Store as frozen liquid at -75°C±15°C for long term storage.
 - Emergency Use vials are labeled as -70°C±10°C, however they can be safely stored in a freezer set to the USP condition of -75°C±15°C
- Frozen vials at have a 6 month expiry from the date of manufacture
- Different size of ULT freezers are available in the market.

A small size (under or over the countertop ULT Freezers can store as much as 30K doses)









- Within 24 hours of receipt and after opening the thermal shipper, replenish/inspect with dry ice (using proper personal protective equipment and dry ice handling).
- With every re-icing, thermal shipper can maintain ultra-low temperature storage for 5 days with 2 openings per day.
- Local dry ice suppliers can be used for re-icing the thermal shipper.
- The thermal shipper should be returned within 10 business days and no later than 20 business days including temperature data logger (picked up by Pfizer/BioNTech contracted supplier)
- Apply appropriate dry ice temperature monitor





- Can be stored at 2 to 8°C up to 5 days
- Room temperature storage is no more than 2 hours.
- Thawing: 3 hours at 2 to 8°C or 30 min at room temperature.
- Post-dilution in use period is 6 hours.

*Product temperature must always be monitored to ensure adherence to temperature requirements for different storage conditions are being met in alignment with site Standard Operating Procedures.

Please note that it is possible that the final preparation and logistical requirements may change in light of forthcoming data on dosing, stability, manufacturing and shipping requirements, but this deck reflects the Company's current understanding based on the totality of available data currently. Current as of September 8, 2020.





Please see slide 2 for important limitations with respect to this presentation.



Provider Enrollment

- Qualtrics platform is being used for enrollment <u>https://dohsd.sjc1.qualtrics.com/jfe/form/SV_eVYZ1Iht9aCoHFX</u>
- Provider Agreement
- Provider Profile
- Assigning of Unique Provider COVID Vaccine Number



Documentation of COVID Vaccination

- SDIIS is preferred method of documentation
- Can use EMR if an HL7 connection is established to SDIIS
- Vaccines must be documented within 24 hours of administration
- Inventory is reported to vaccinefinder.org daily more info to come



Contact Information

Angela Jackley Deputy Administrator, Office of Disease Prevention Services. Vaccination Lead

Tim Heath Immunization Program Coordinator, Vaccination colead tim.heath@state.sd.us

Brett Oakland Immunization Registry Coordinator brett.oakland@state.sd.us

Carol Chalcraft Immunization Education Coordinator carol.chalcraft@state.sd.us

Misty Pickner Vaccine Management Specialist misty.pickner@state.sd.us

